How Much Dividend Does Revance Therapeutics Inc. (RVNC) Pay?

0
8
KOSK
KOSK

Revance Therapeutics Inc. (NASDAQ:RVNC) finished Wednesday with a subtraction of -$0.21 to close at $25.80, a downside of -0.81 percent. An average of 1,684,940 shares of common stock have been traded in the last five days. There was a fall of -$1.73 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 2,224,895 shares traded, while the 50-day average volume stands at 1,297,394.

RVNC stock has increased by 21.41% in the last month. The company shares reached their 1-month lowest point of $19.15 on 08/29/22. With the stock rallying to its 52-week high on 09/09/22, shares of the company touched a low of $11.27 and a high of $30.00 in 52 weeks. It has reached a new high 13 times so far this year and achieved 58.09% or $9.48 in price. In spite of this, the price is down -14.00% from the 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Insider Transactions

8 days have passed since Revance Therapeutics Inc. (RVNC) last reported insider trading activity. Moxie Dwight, who is SVP, GC & Secretary, most recently acquired $11,000 shares at $27.07 per share on Sep 14. In this transaction, the insider spent $297,798. SVP, GC & Secretary, Moxie Dwight, disposed of 1,675 shares at a price of $30.00 on Sep 27. The insider now owns more than $50,250 worth of shares.

Valuation Metrics

Revance Therapeutics Inc. (RVNC) stock’s beta is 0.87. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 21.46.

Financial Health

The quick ratio of Revance Therapeutics Inc. for the three months ended March 30 was 3.20, and the current ratio was 3.40, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at $54.39 million compared to revenue of $77.8 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Revance Therapeutics Inc.’s return on assets was -45.50%.

Earnings Surprise

For the three-month period that ended March 30, Revance Therapeutics Inc. had $164.4 million in cash and short-term investments compared to $378.38 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$61.44 million in the quarter, while revenues of -$64.34 million were shrunk -17.51%. The analyst consensus anticipated Revance Therapeutics Inc.’s latest quarter earnings to come in at -$0.83 per share, but it turned out to be -$0.94, a -13.30% surprise. For the quarter, EBITDA amounted to -$50.83 million. Shareholders own equity worth $73.11 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Revance Therapeutics Inc. (RVNC) price momentum. RSI 9-day as of the close on 21 September was 57.85%, suggesting the stock is Neutral, with historical volatility in this time frame at 74.10%.

As of today, RVNC’s price is $26.15 -6.28% or -$1.73 from its 5-day moving average. RVNC is currently trading +21.58% higher than its 20-day SMA and +55.52% higher than its 100-day SMA. However, the stock’s current price level is +75.03% above the SMA50 and +76.71% above the SMA200.

The stochastic %K and %D were 65.89% and 67.19%, respectively, and the average true range (ATR) was 1.68. With the 14-day stochastic at 62.45% and the average true range at 1.61, the RSI (14) stands at 60.38%. The stock has reached -0.73 on the 9-day MACD Oscillator while the 14-day reading was at 1.08.

Analyst Ratings

Wells Fargo downgraded Revance Therapeutics Inc. (NASDAQ: RVNC) to a an Equal weight rating in its most recent analyst report. Previously, the stock was rated as an Overweight.

LEAVE A REPLY

Please enter your comment!
Please enter your name here